BioSpace News Archive

Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.

Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.

BioSpace takes a look at some of the most recent IPO plans from companies across the globe.

The amount of scientific information unearthed about SARS-CoV-2, the virus that causes COVID-19, in only six months is unprecedented. The speed is remarkable, although much of it will still need to be confirmed over time with more careful study. Still, each day presents new data with a glimmer of hope. Here’s a look at some recent findings.

Although clinical trials are often performed throughout different parts of the world, often their demographic makeup—the gender, age and race of participants—has a certain kind of uniformity.

It was a fairly busy week with clinical trial updates and announcements. Here’s a look.

Decentralized clinical trials gained a foothold in the pharmaceutical industry amidst the COVID-19 pandemic and will continue to be used once the pandemic ends, according to panelists at BIO 2020, speaking Thursday in a virtual session.

The FDA approved Viela Bio’s Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive. About 80% of all NMOSD patients test positive for anti-AQP4 antibodies.

For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatment For the IMbark Phase 2 clinical trial, the analyses correlate the potential improvement in overall survival from imetelstat treatment with other clinical benefits observed in the trial, such as fibrosis improvement, as well as symptom and spleen response Data provide further support of ongoing and pla

Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a webcast panel session titled Cell Therapy: Promise of the Next Generation at the Raymond James Human Healthcare Innovation Conference on Wednesday, June 17, 2020, at 12:00 p.m. ET. The virtual panel will be hosted by equity research analysts Dane Leone and David Novak. To access the live w